Handa Pharmaceuticals, Inc. (TPEX:6620)

Market Cap	23.21B
Revenue (ttm)	1.34B
Net Income (ttm)	620.70M
Shares Out	156.86M
EPS (ttm)	4.23
PE Ratio	34.96
Forward PE	n/a
Dividend	1.51 (1.02%)
Ex-Dividend Date	Jul 2, 2025

Volume	1,285,739
Average Volume	1,266,366
Open	148.50
Previous Close	143.00
Day's Range	144.50 - 153.50
52-Week Range	49.90 - 153.50
Beta	0.93
RSI	81.54
Earnings Date	Dec 26, 2025

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6620

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.